• Leyre Riancho-Zarrabeitia, Vanesa Calvo-Río, Ricardo Blanco, Marina Mesquida, Alfredo M Adan, José M Herreras, Ángel Aparicio, Diana Peiteado-Lopez, Miguel Cordero-Coma, José Luis García Serrano, Norberto Ortego-Centeno, Olga Maíz, Ana Blanco, Juan Sánchez-Bursón, Senén González-Suárez, Alejandro Fonollosa, Montserrat Santos-Gómez, Carmen González-Vela, Javier Loricera, Trinitario Pina, and Miguel A González-Gay.
• Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Avda. Valdecilla s/n., Santander ES-39008, Spain.
• Semin. Arthritis Rheum. 2015 Dec 1; 45 (3): 361-8.

ObjectivesTo assess anti-TNF-α therapy response in uveitis associated with sarcoidosis refractory to conventional immunosuppressive therapy.MethodsOpen-label, multicenter, retrospective study on patients with sarcoid uveitis who underwent anti-TNF-α therapy because of inadequate response to conventional therapy including corticosteroids and at least 1 systemic synthetic immunosuppressive drug. The main outcome measurements were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness, and immunosuppression load.ResultsA total of 17 patients (8 men; 29 affected eyes; mean ± standard deviation age 38.4 ± 16.8; range: 13-76 years) were studied. The patients had bilateral hilar lymphadenopathy (58.8%), lung parenchyma involvement (47.1%), peripheral lymph nodes (41.2%), and involvement of other organs (52.9%). Angiotensin-converting enzyme was elevated in 58.8%. The most frequent ocular pattern was bilateral chronic relapsing panuveitis. The first biologic agent used was adalimumab in 10 (58.8%) and infliximab in 7 (41.2%) cases. Infliximab 5mg/kg intravenously every 4-8 weeks and adalimumab 40mg subcutaneously every 2 weeks were the most common administration patterns. In most cases anti-TNF-α therapy was given in combination with immunosuppressive drugs. The mean duration of follow-up was 33.9 ± 17.1 months. Significant improvement was observed following anti-TNF-α therapy. Baseline results versus results at 2 years from the onset of biologic therapy were the following: the median of cells in the ocular anterior chamber (interquartile range-IQR) 0.5 (0-2) versus 0 (0-0) (p = 0.003), vitritis 0 (0-1.25) versus 0 (0-0) (p = 0.008), macular thickness (391.1 ± 58.8 versus 247 ± 40.5µm) (p = 0.028), and visual acuity 0.60 ± 0.33 versus 0.74 ± 0.27; p = 0.009. The median daily (interquartile range) dose of prednisone was also reduced from 10 (0-30)mg at the onset of the anti-TNF-α therapy to 0 (0-0)mg at 2 years (p = 0.02). Significant reduction was also achieved in the immunosuppressive load.ConclusionAnti-TNF-α therapy is effective in sarcoid uveitis patients refractory to conventional immunosuppressive therapy. Infliximab and adalimumab allowed a substantial reduction in prednisone dose despite having failed standard therapy.Copyright © 2015 Elsevier Inc. All rights reserved.

31 keywords...

hide…